Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + docetaxel
- Development stage
- Unknown
- Lead developer
- Bayer Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of sorafenib, a multikinase inhibitor targeting multiple tyrosine kinases, and docetaxel, a taxane derivative that acts as a mitotic inhibitor. Docetaxel binds to tubulin, promoting assembly and inhibiting disassembly of microtubules, leading to inhibition of cell division and tumor proliferation. Sorafenib inhibits multiple tyrosine kinases involved in tumor growth and angiogenesis. This combination has been studied in various cancer types including gastric cancer, breast cancer, and prostate cancer.
- Brand names
- TaxotereNexavar
- Other names
- Docefrez (for docetaxel)
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)BCL-2 (BCL-2 family)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))FGFR1 (Fibroblast growth factor receptor 1)RAF1 (c-Raf-1 (Y340D/Y341D))PDGFRB (Platelet-derived growth factor receptor beta)RK (Ribokinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)BRAF (B-Raf proto-oncogene, serine/threonine kinase)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sorafenib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + docetaxel.